| pubmed-article:12168107 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:12168107 | lifeskim:mentions | umls-concept:C2239176 | lld:lifeskim |
| pubmed-article:12168107 | lifeskim:mentions | umls-concept:C1533685 | lld:lifeskim |
| pubmed-article:12168107 | lifeskim:mentions | umls-concept:C0001962 | lld:lifeskim |
| pubmed-article:12168107 | lifeskim:mentions | umls-concept:C0009429 | lld:lifeskim |
| pubmed-article:12168107 | lifeskim:mentions | umls-concept:C0522523 | lld:lifeskim |
| pubmed-article:12168107 | lifeskim:mentions | umls-concept:C1522326 | lld:lifeskim |
| pubmed-article:12168107 | lifeskim:mentions | umls-concept:C0850292 | lld:lifeskim |
| pubmed-article:12168107 | lifeskim:mentions | umls-concept:C1292734 | lld:lifeskim |
| pubmed-article:12168107 | lifeskim:mentions | umls-concept:C0556895 | lld:lifeskim |
| pubmed-article:12168107 | pubmed:issue | 3 | lld:pubmed |
| pubmed-article:12168107 | pubmed:dateCreated | 2002-8-8 | lld:pubmed |
| pubmed-article:12168107 | pubmed:abstractText | Radiofrequency ablation (RFA) is an effective modality for the treatment of hepatocellular carcinoma (HCC), because it can induce large coagulated necrosis in a few sessions. We have recently reported that the combination therapy of percutaneous ethanol injection (PEI) with RFA (PEI-RFA) created enhancement of coagulated necrosis compared with RFA alone. In the present study, we adopted PEI-RFA for the treatment of HCCs located in the regions that are difficult to treat with RFA alone. Five patients with biopsy-proven HCC and liver cirrhosis underwent PEI-RFA therapy. In these patients, HCCs were located beside the gallbladder, inferior vena cava or portal vein or kidney, or immediately under the diaphragm. Prior to RFA, 99.5% ethanol was injected into the region of HCC located in the regions where RFA energy appears to be difficult to reach. In all cases, HCC was totally coagulated by PEI-RFA. Injecting ethanol prior to RFA therapy caused no major side effects. These results indicate that PEI-RFA may be effective for the treatment of HCCs located in the regions that are difficult to treat with RFA alone as well as large-sized HCCs. | lld:pubmed |
| pubmed-article:12168107 | pubmed:language | eng | lld:pubmed |
| pubmed-article:12168107 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12168107 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:12168107 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:12168107 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:12168107 | pubmed:month | Sep | lld:pubmed |
| pubmed-article:12168107 | pubmed:issn | 1019-6439 | lld:pubmed |
| pubmed-article:12168107 | pubmed:author | pubmed-author:MurotaMasayuk... | lld:pubmed |
| pubmed-article:12168107 | pubmed:author | pubmed-author:KuriyamaShige... | lld:pubmed |
| pubmed-article:12168107 | pubmed:author | pubmed-author:YoshidaShuhei... | lld:pubmed |
| pubmed-article:12168107 | pubmed:author | pubmed-author:ArimaKeijiK | lld:pubmed |
| pubmed-article:12168107 | pubmed:author | pubmed-author:MasakiTsutomu... | lld:pubmed |
| pubmed-article:12168107 | pubmed:author | pubmed-author:HosomiNaokiN | lld:pubmed |
| pubmed-article:12168107 | pubmed:author | pubmed-author:FunakiToshiha... | lld:pubmed |
| pubmed-article:12168107 | pubmed:author | pubmed-author:WatanabeSeish... | lld:pubmed |
| pubmed-article:12168107 | pubmed:author | pubmed-author:NakaiSeijiS | lld:pubmed |
| pubmed-article:12168107 | pubmed:author | pubmed-author:KurokohchiKaz... | lld:pubmed |
| pubmed-article:12168107 | pubmed:author | pubmed-author:MiyauchiYoshi... | lld:pubmed |
| pubmed-article:12168107 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:12168107 | pubmed:volume | 21 | lld:pubmed |
| pubmed-article:12168107 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:12168107 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:12168107 | pubmed:pagination | 611-5 | lld:pubmed |
| pubmed-article:12168107 | pubmed:dateRevised | 2004-11-17 | lld:pubmed |
| pubmed-article:12168107 | pubmed:meshHeading | pubmed-meshheading:12168107... | lld:pubmed |
| pubmed-article:12168107 | pubmed:meshHeading | pubmed-meshheading:12168107... | lld:pubmed |
| pubmed-article:12168107 | pubmed:meshHeading | pubmed-meshheading:12168107... | lld:pubmed |
| pubmed-article:12168107 | pubmed:meshHeading | pubmed-meshheading:12168107... | lld:pubmed |
| pubmed-article:12168107 | pubmed:meshHeading | pubmed-meshheading:12168107... | lld:pubmed |
| pubmed-article:12168107 | pubmed:meshHeading | pubmed-meshheading:12168107... | lld:pubmed |
| pubmed-article:12168107 | pubmed:meshHeading | pubmed-meshheading:12168107... | lld:pubmed |
| pubmed-article:12168107 | pubmed:meshHeading | pubmed-meshheading:12168107... | lld:pubmed |
| pubmed-article:12168107 | pubmed:meshHeading | pubmed-meshheading:12168107... | lld:pubmed |
| pubmed-article:12168107 | pubmed:meshHeading | pubmed-meshheading:12168107... | lld:pubmed |
| pubmed-article:12168107 | pubmed:year | 2002 | lld:pubmed |
| pubmed-article:12168107 | pubmed:articleTitle | Combination therapy of percutaneous ethanol injection and radiofrequency ablation against hepatocellular carcinomas difficult to treat. | lld:pubmed |
| pubmed-article:12168107 | pubmed:affiliation | Third Department of Internal Medicine, Kagawa Medical University, 1750-1 Ikenobe, Miki-cho, Kagawa 761-0793, Japan. | lld:pubmed |
| pubmed-article:12168107 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:12168107 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:12168107 | lld:pubmed |
